Protective Effect of Myricetin, Apigenin, and Hesperidin Pretreatments on Cyclophosphamide-Induced Immunosuppression

dc.contributor.author Berkoz, Mehmet
dc.contributor.author Yalin, Serap
dc.contributor.author Ozkan-Yilmaz, Ferbal
dc.contributor.author Ozluer-Hunt, Arzu
dc.contributor.author Krosniak, Miroslaw
dc.contributor.author Francik, Renata
dc.contributor.author Yildirim, Metin
dc.date.accessioned 2025-05-10T17:10:08Z
dc.date.available 2025-05-10T17:10:08Z
dc.date.issued 2021
dc.description Francik, Renata/0000-0002-7071-8072; Adiyaman, Abdullah/0000-0002-3049-9813; Berkoz, Mehmet/0000-0003-4219-8054 en_US
dc.description.abstract Aim: Major side effects of cyclophosphamide administration are immunosuppression and myelosuppression. The immunomodulatory effects of plant bioactive compounds on chemotherapy drug-induced immunosuppression may have significant effects in cancer treatment. For this reason, we investigated the immunomodulatory effect of myricetin, apigenin, and hesperidin in cyclophosphamide-induced immunosuppression in rats. Methods: In our study, a total of 64 rats were used, and divided into eight equal groups. These groups were: control, cyclophosphamide, cyclophosphamide+myricetin (100mg/kg), cyclophosphamide+myricetin (200mg/kg), cyclophosphamide+apigenin (100mg/kg), cyclophosphamide+apigenin (200mg/kg), cyclophosphamide+hesperidin (100mg/kg), and cyclophosphamide+hesperidin (200mg/kg). Myricetin, apigenin, and hesperidin pretreatments were performed for 14d, while cyclophosphamide application (200mg/kg) was performed only on the 4th day of the study. Levels of humoral antibody production, quantitative hemolysis, macrophage phagocytosis, splenic lymphocyte proliferation, and natural killer cell cytotoxicity were determined. In addition, we measured pro-inflammatory cytokines, and followed lipid peroxidation and antioxidant markers and examined the histology of bone marrow, liver and spleen in all groups. Results: During cyclophosphamide treatment, all three phytochemicals increased the levels of humoral antibody production, quantitative hemolysis, macrophage phagocytosis, splenic lymphocyte proliferation, antioxidant markers, and natural killer cell cytotoxicity. Moreover, the agents decreased the levels of pro-inflammatory cytokines and mediators, reduced lipid peroxidation markers, and reduced tissue damage in liver, spleen, and bone marrow. Conclusion: Our study demonstrated that myricetin, apigenin, and hesperidin can reduce the immunosuppressive effect of cyclophosphamide by enhancing both innate and adaptive immune responses, and these compounds may be useful immunomodulatory agents during cancer chemotherapy. en_US
dc.description.sponsorship Office of Scientific Research Projects of Van Yuzuncu Yil University [THD-2019-7853] en_US
dc.description.sponsorship This research was financially supported by the Office of Scientific Research Projects of Van Yuzuncu Yil University under Grant number [THD-2019-7853]. en_US
dc.identifier.doi 10.1080/08923973.2021.1916525
dc.identifier.issn 0892-3973
dc.identifier.issn 1532-2513
dc.identifier.scopus 2-s2.0-85105181963
dc.identifier.uri https://doi.org/10.1080/08923973.2021.1916525
dc.identifier.uri https://hdl.handle.net/20.500.14720/7323
dc.language.iso en en_US
dc.publisher Taylor & Francis Ltd en_US
dc.rights info:eu-repo/semantics/closedAccess en_US
dc.subject Cyclophosphamide en_US
dc.subject Immunomodulatory Effect en_US
dc.subject Myricetin en_US
dc.subject Apigenin en_US
dc.subject Hesperidin en_US
dc.title Protective Effect of Myricetin, Apigenin, and Hesperidin Pretreatments on Cyclophosphamide-Induced Immunosuppression en_US
dc.type Article en_US
dspace.entity.type Publication
gdc.author.id Francik, Renata/0000-0002-7071-8072
gdc.author.id Adiyaman, Abdullah/0000-0002-3049-9813
gdc.author.id Berkoz, Mehmet/0000-0003-4219-8054
gdc.author.scopusid 12801030200
gdc.author.scopusid 8608387300
gdc.author.scopusid 24335459700
gdc.author.scopusid 25030856200
gdc.author.scopusid 6602345446
gdc.author.scopusid 8367498800
gdc.author.scopusid 57223205516
gdc.author.wosid Yalın, Serap/L-7402-2017
gdc.author.wosid Ozluer Hunt, Arzu/F-8773-2015
gdc.author.wosid Adıyaman, Abdullah/Hge-2569-2022
gdc.author.wosid Yılmaz, Ferbal/L-9821-2015
gdc.author.wosid Yldrm, Mtn/Jmp-9922-2023
gdc.author.wosid Francik, Renata/Aab-4791-2020
gdc.coar.access metadata only access
gdc.coar.type text::journal::journal article
gdc.description.department T.C. Van Yüzüncü Yıl Üniversitesi en_US
gdc.description.departmenttemp [Berkoz, Mehmet; Gezici, Hava; Yigit, Ayhan; Unal, Seda; Volkan, Davut] Van Yuzuncu Yil Univ, Fac Pharm, Dept Biochem, Zeve Campus, TR-65080 Van, Turkey; [Yalin, Serap] Mersin Univ, Fac Pharm, Dept Biochem, Mersin, Turkey; [Ozkan-Yilmaz, Ferbal] Mersin Univ, Dept Basic Sci, Fac Fisheries, Mersin, Turkey; [Ozluer-Hunt, Arzu] Mersin Univ, Fac Fisheries, Dept Aquaculture, Mersin, Turkey; [Krosniak, Miroslaw] Jagiellonian Univ, Med Coll, Dept Food Chem & Nutr, Krakow, Poland; [Francik, Renata] Jagiellonian Univ, Med Coll, Dept Bioorgan Chem, Krakow, Poland; [Yunusoglu, Oruc] Van Yuzuncu Yil Univ, Fac Med, Dept Med Pharmacol, Van, Turkey; [Adiyaman, Abdullah] Van Yuzuncu Yil Univ, Fac Pharm, Dept Pharmaceut Biotechnol, Van, Turkey; [Yildirim, Metin] Tarsus Univ, Vocat Sch Hlth Serv, Dept Pharm Serv, Mersin, Turkey en_US
gdc.description.endpage 369 en_US
gdc.description.issue 3 en_US
gdc.description.publicationcategory Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı en_US
gdc.description.scopusquality Q3
gdc.description.startpage 353 en_US
gdc.description.volume 43 en_US
gdc.description.woscitationindex Science Citation Index Expanded
gdc.description.wosquality Q2
gdc.identifier.pmid 33905277
gdc.identifier.wos WOS:000663549900001
gdc.index.type WoS
gdc.index.type Scopus
gdc.index.type PubMed

Files